Abstract
Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P
| Original language | English |
|---|---|
| Pages (from-to) | 857-864 |
| Number of pages | 8 |
| Journal | Clinical Journal of Pain |
| Volume | 29 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2013 |
Fingerprint
Keywords
- Botulinum toxin
- Herpes zoster
- Neuropathic pain
- Postherpetic neuralgia
- Randomized clinical trial
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
- Clinical Neurology
Cite this
Botulinum toxin a in postherpetic neuralgia : A parallel, randomized, double-blind, single-dose, placebo-controlled trial. / Apalla, Zoe; Sotiriou, Elena; Lallas, Aimilios; Lazaridou, Elizabeth; Ioannides, Demetrios.
In: Clinical Journal of Pain, Vol. 29, No. 10, 10.2013, p. 857-864.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Botulinum toxin a in postherpetic neuralgia
T2 - A parallel, randomized, double-blind, single-dose, placebo-controlled trial
AU - Apalla, Zoe
AU - Sotiriou, Elena
AU - Lallas, Aimilios
AU - Lazaridou, Elizabeth
AU - Ioannides, Demetrios
PY - 2013/10
Y1 - 2013/10
N2 - Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P
AB - Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods: Thirty adults with PHN were randomized either to BTXA or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results: Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P
KW - Botulinum toxin
KW - Herpes zoster
KW - Neuropathic pain
KW - Postherpetic neuralgia
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=84888005745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888005745&partnerID=8YFLogxK
U2 - 10.1097/AJP.0b013e31827a72d2
DO - 10.1097/AJP.0b013e31827a72d2
M3 - Article
C2 - 23370074
AN - SCOPUS:84888005745
VL - 29
SP - 857
EP - 864
JO - Clinical Journal of Pain
JF - Clinical Journal of Pain
SN - 0749-8047
IS - 10
ER -